Oramed Pharmaceuticals announces key developments, including its inclusion in the Russell 2000 and 3000 indices, significant loan repayments, and a strong financial position.

Oramed Pharmaceuticals has announced an $18 million payment from Scilex Holdings, raising total returns to $118 million. A cash dividend of $0.25 per share has also been approved.

Oramed Pharmaceuticals has revealed its new Rights Agreement, aiming to protect shareholders during takeover attempts while distributing rights as a dividend.

Oramed Pharmaceuticals Inc. announces impressive financial results for the third quarter of 2025, showing robust growth and strategic investments that led to significant income gains.

Oramed Pharmaceuticals has released a letter outlining key advancements in its oral insulin program and robust investment strategies that underline its commitment to shareholder value and growth.

Oramed Pharmaceuticals has announced a $36.9 million investment and collaboration with Alpha Tau Medical to advance innovative cancer therapies. This partnership aims to enhance Oramed's market capabilities in therapeutic delivery.

In a recent communication, Oramed Pharmaceuticals outlined major achievements and future plans, including the formation of a new joint venture aiming to innovate oral insulin delivery.